- Selected by the FTSE4Good Developed Index for the 15th consecutive year
- Named to the MSCI ESG Leaders Index for the 10th consecutive year
- Rigorously evaluated by indices measuring strong performance on ESG criteria
OSAKA, Japan-Thursday 11 July 2019 [ AETOS Wire ]
(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) today announced that it has been selected for the 15th consecutive year by the FTSE4Good Developed Index, one of the world’s premier indices for Socially Responsible Investment (SRI), created by FTSE Russell.* In addition, Takeda was named to the MSCI ESG Leaders Index for the 10th consecutive year. Both indices target companies demonstrating the strongest environmental, social and governance (ESG) practices. Takeda has been highly recognized for strengthening its ESG business practices and information disclosure, particularly regarding its proactive management of environmental issues, as well as its Access to Medicines Strategy, which seeks to help address the unmet needs of patients in underserved communities around the world. Takeda ranked fifth in the 2018 Access to Medicine Index, climbing 10 places in this independent ranking of the world’s largest pharmaceutical companies.
On the FTSE4Good Developed Index, Takeda received high marks in the areas of “Climate Change,” “Customer Responsibility,” and “Corporate Governance.” Takeda’s proactive approach to tackling environmental issues on a global scale includes setting clear targets for CO2 emissions reduction and other related benchmarks. Its performance in this ranking also reflect strengthening corporate social responsibility (CSR) activities and information disclosure. With the latest overall score, Takeda now outperforms the pharmaceutical industry average and Japan country average across all themes – environment, social, and governance.
Takeda earned recognition from MSCI ESG Leaders Index for its progress towards tackling issues related to the environmental impact of emissions, access to health care, and anti-corruption. MSCI focuses on companies that have the highest ESG rated performance in each sector to help institutional investors more effectively integrate ESG considerations into their investment processes, as well as manage, measure, and report on ESG mandates.
As a pharmaceutical company dedicated to improving people’s lives, Takeda remains committed to fulfilling its social responsibilities while creating sustainable value in response to global needs.
Takeda has been selected by multiple benchmark ESG indices:
* An independent company owned by the London Stock Exchange, FTSE Russell provides global index and analytical solutions.
** A specific group or category of investments that share certain characteristics.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases, and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit www.takeda.com
About Takeda’s Sustainable Value Report
Takeda’s annual Sustainable Value Report showcases how the company is addressing the world’s biggest challenges to sustainable development over the long-term. Data included are primarily non-financial, focusing on Takeda’s diverse CSR/ESG (sustainability) commitments, as well as how CSR/ESG priorities are inextricably linked to the company’s DNA. Takeda leverages such benchmarks as the international integrated reporting framework of the International Integrated Reporting Council (IIRC), United Nations Global Compact’s advanced level assessment criteria, and Global Reporting Initiative (GRI) Standards to create a comprehensive report that incorporates high standards of transparency and disclosure, targeting a broad range of stakeholders.
For more information, visit https://www.takeda.com/corporate-responsibility/Sustainable-Value-Report/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190709005384/en/
Contacts
Media Contact:
Takeda Pharmaceutical Company Limited
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095
Permalink : https://www.aetoswire.com/news/takeda-continues-ongoing-inclusion-in-the-ftse4good-developed-indexnbspamp-msci-esg-leaders-index/en
- Named to the MSCI ESG Leaders Index for the 10th consecutive year
- Rigorously evaluated by indices measuring strong performance on ESG criteria
OSAKA, Japan-Thursday 11 July 2019 [ AETOS Wire ]
(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) today announced that it has been selected for the 15th consecutive year by the FTSE4Good Developed Index, one of the world’s premier indices for Socially Responsible Investment (SRI), created by FTSE Russell.* In addition, Takeda was named to the MSCI ESG Leaders Index for the 10th consecutive year. Both indices target companies demonstrating the strongest environmental, social and governance (ESG) practices. Takeda has been highly recognized for strengthening its ESG business practices and information disclosure, particularly regarding its proactive management of environmental issues, as well as its Access to Medicines Strategy, which seeks to help address the unmet needs of patients in underserved communities around the world. Takeda ranked fifth in the 2018 Access to Medicine Index, climbing 10 places in this independent ranking of the world’s largest pharmaceutical companies.
On the FTSE4Good Developed Index, Takeda received high marks in the areas of “Climate Change,” “Customer Responsibility,” and “Corporate Governance.” Takeda’s proactive approach to tackling environmental issues on a global scale includes setting clear targets for CO2 emissions reduction and other related benchmarks. Its performance in this ranking also reflect strengthening corporate social responsibility (CSR) activities and information disclosure. With the latest overall score, Takeda now outperforms the pharmaceutical industry average and Japan country average across all themes – environment, social, and governance.
Takeda earned recognition from MSCI ESG Leaders Index for its progress towards tackling issues related to the environmental impact of emissions, access to health care, and anti-corruption. MSCI focuses on companies that have the highest ESG rated performance in each sector to help institutional investors more effectively integrate ESG considerations into their investment processes, as well as manage, measure, and report on ESG mandates.
As a pharmaceutical company dedicated to improving people’s lives, Takeda remains committed to fulfilling its social responsibilities while creating sustainable value in response to global needs.
Takeda has been selected by multiple benchmark ESG indices:
Name of Index/ Investment Universe**/Ratings
|
Company/Organization
|
Country
|
Number of selection
|
|
Dow Jones Sustainability Asia Pacific Index
|
S&P Dow Jones Indices
|
US
|
9th consecutive year
|
|
Ethibel EXCELLENCE Investment Register
|
Forum Ethibel
|
BEL
|
From July 2017
|
|
Prime Status
|
Oekom
|
GER
|
2nd consecutive year
|
|
Industry Mover Sustainability Yearbook Award 2019
|
RobecoSAM
|
CHE
|
First time
|
|
Global 100 Most Sustainable Corporations in the World Index
|
Corporate Knights
|
CND
|
4th consecutive year
|
* An independent company owned by the London Stock Exchange, FTSE Russell provides global index and analytical solutions.
** A specific group or category of investments that share certain characteristics.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases, and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit www.takeda.com
About Takeda’s Sustainable Value Report
Takeda’s annual Sustainable Value Report showcases how the company is addressing the world’s biggest challenges to sustainable development over the long-term. Data included are primarily non-financial, focusing on Takeda’s diverse CSR/ESG (sustainability) commitments, as well as how CSR/ESG priorities are inextricably linked to the company’s DNA. Takeda leverages such benchmarks as the international integrated reporting framework of the International Integrated Reporting Council (IIRC), United Nations Global Compact’s advanced level assessment criteria, and Global Reporting Initiative (GRI) Standards to create a comprehensive report that incorporates high standards of transparency and disclosure, targeting a broad range of stakeholders.
For more information, visit https://www.takeda.com/corporate-responsibility/Sustainable-Value-Report/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190709005384/en/
Contacts
Media Contact:
Takeda Pharmaceutical Company Limited
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095
Permalink : https://www.aetoswire.com/news/takeda-continues-ongoing-inclusion-in-the-ftse4good-developed-indexnbspamp-msci-esg-leaders-index/en